Asthma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sanofi, Zura Bio Ltd., AstraZeneca, and others.
DelveInsight’s, “Asthma Pipeline Insight 2023” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in Asthma pipeline landscape. It covers the Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Asthma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Asthma Pipeline Report
- DelveInsight’s Asthma pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline therapies for Asthma treatment.
- The leading companies working in the Asthma Market include Jiangsu Hengrui Medicine, GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., ARS Pharmaceuticals, Sanofi, Zura Bio Ltd., AstraZeneca, EURRUS Biotech GmbH, T-Balance Therapeutics GmbH, Gossamer Bio, Aldeyra Therapeutics, Inc., Trio Medicines, Janssen Research & Development, Arrowhead Pharmaceuticals, Hoffman-La-Roche, GlaxoSmithKline, Biohaven Pharmaceutical, TAK-Circulator Co., Shanghai Hengrui Pharmaceutical, and others.
- Promising Asthma Pipeline Therapies in the various stages of development include DUPIXENT®, Tezepelumab, MEDI9929, Revamilast, Benralizumab, AZD7594, GSK3511294 (Depemokimab), and others.
- November 2023: AstraZeneca announced a study of Phase 3 clinical triails for Tezepelumab. This is a regional, multicentre, randomized, double-blind, placebo controlled, parallel group, phase 3 study designed to evaluate the efficacy and safety of 210 mg Q4W (SC) of tezepelumab in adults with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 396 participants will be randomized regionally (China/non-China). Participants will receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 52-week treatment period. The study also includes a post-treatment follow-up period of 12 weeks.
- December 2023: Sanofi announced a study of Phase 4 clinical trials for Dupilumab. This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma. The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.
Request a sample and discover the recent advances in Asthma Treatment Drugs @ Asthma Pipeline Outlook Report
In the Asthma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Asthma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Asthma Overview
Asthma is a chronic disease that affects the airways. Asthma is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen.
Find out more about Asthma Treatment Landscape @ Drugs for Asthma Treatment
Asthma Emerging Drugs Profile
- Dexpramipexole: Areteia Therapeutics
- TQC2731: Chia Tai Tianqing Pharmaceutical Group
- SHR-1703: Jiangsu HengRui Medicine
Asthma Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the Asthma therapies. The Asthma Companies which have their Asthma drug candidates in the most advanced stage, i.e. phase III include, Areteia Therapeutics.
DelveInsight’s Asthma pipeline report covers around 100+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
Asthma Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Learn more about the emerging Asthma Pipeline Therapies @ Asthma Clinical Trials Assessment
Scope of the Asthma Pipeline Report
- Coverage- Global
- Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Asthma Companies- Jiangsu Hengrui Medicine, GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., ARS Pharmaceuticals, Sanofi, Zura Bio Ltd., AstraZeneca, EURRUS Biotech GmbH, T-Balance Therapeutics GmbH, Gossamer Bio, Aldeyra Therapeutics, Inc., Trio Medicines, Janssen Research & Development, Arrowhead Pharmaceuticals, Hoffman-La-Roche, GlaxoSmithKline, Biohaven Pharmaceutical, TAK-Circulator Co., Shanghai Hengrui Pharmaceutical, and others.
- Asthma Pipeline Therapies- DUPIXENT®, Tezepelumab, MEDI9929, Revamilast, Benralizumab, AZD7594, GSK3511294 (Depemokimab), and others.
Dive deep into rich insights for new drugs for Asthma Treatment, Visit @ Asthma Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Asthma Executive Summary
- Asthma: Overview
- Asthma Pipeline Therapeutics
- Asthma Pipeline Therapeutic Assessment
- Asthma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- PT-027: Avillion LLP
- Mid Stage Products (Phase II/III)
- PT001: Pearl Therapeutics (AstraZeneca)
- Mid Stage Products (Phase II)
- FP 025: Foresee Pharmaceuticals
- Early Stage Products (Phase I/II)
- AQ-001S: Aquilon Pharmaceuticals S.A
- Early Stage Products (Phase I)
- Itolizumab (EQ001): Equillium
- Preclinical and Discovery Stage Products
- KBP7026: KBP Biosciences
- Inactive Products
- Asthma Key Companies
- Asthma Key Products
- Asthma- Unmet Needs
- Asthma- Market Drivers and Barriers
- Asthma- Future Perspectives and Conclusion
- Asthma Analyst Views
- Asthma Key Companies
- Appendix
For further information on the Asthma Pipeline Therapeutics, reach out @ Asthma Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market
